Advancements in Dual-Load Antibody–Drug Conjugates and Challenges with Quality Analysis
Open Access
- 29 May 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 860
Abstract
Antibody–drug conjugates (ADCs) are a pivotal technology for precision cancer therapy, harnessing the synergistic effects of antibody targeting and toxin delivery. However, traditional ADCs encounter limitations in efficacy that stem from tumor resistance, heterogeneity, and intense target competition. Dual-payload ADCs (DP-ADCs) represent a promising solution to these challenges, as they leverage dual mechanisms of action that mitigate acquired drug resistance and enhance adaptability to tumor heterogeneity. The complex structure of DP-ADCs presents substantial quality control hurdles. In this manuscript, we review the current payload selection and conjugation strategies of DP-ADCs and examine recent advances in quality control research. Specifically, we analyze the analytical challenges related to the quantification of free toxins, the determination of the total antibody content, and the characterization of the drug-to-antibody ratio and its distribution. Ultimately, the aim of this work is to provide valuable guidance for future DP-ADC quality control analyses to facilitate their clinical translation and application.Keywords
All Related Versions
Funding Information
- Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project (2025ZD01904200)
- State Key Laboratory of Drug Regulatory Science Project (2025SKLDRS0318)
This publication has 120 references indexed in Scilit:
- Adduct formation by coeluting endogenous biomolecules using ESI-MSAnalytical and Bioanalytical Chemistry, 2025
- Development of antibody‐drug conjugates in cancer: Overview and prospectsCancer Communications, 2023
- Insight into Temperature Dependency and Design of Experiments towards Process Development for Cysteine‐Based Antibody‐Drug ConjugatesChemistrySelect, 2020
- Conjugation Site Analysis by MS/MS Protein Sequencing2019
- Application of triple quadrupole mass spectrometry for the characterization of antibody–drug conjugatesAnalytical and Bioanalytical Chemistry, 2019
- Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug ConjugatesAngewandte Chemie, 2016
- Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometryMass Spectrometry Reviews, 2016
- A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activityBreast Cancer Research and Treatment, 2015
- Characterization of Cysteine-Linked Conjugation Profiles of Immunoglobulin G1 and Immunoglobulin G2 Antibody–Drug ConjugatesJournal of Pharmaceutical Sciences, 2015
- Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy2013